KRAS and non-small cell lung carcinoma: Although immune checkpoint inhibitors of programmed death 1 (PD1) and programmed death ligand 1 (PD‐L1) have been approved for NSCLC, they fail to discriminate KRAS‐mutant from other NSCLC (Jeanson et al, 2019).